Duloxetine
Product Images NDC 68788-9301

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-9301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap Usp 30mg

Label for Duloxetine Delayed-Release Capsule USP 30mg, a generic for Cymbalta, manufactured by Breckenridge Pharmaceuticals, Inc. The label includes dosage form as capsules, strength 30mg, storage instructions, and caution about federal law restricting drug transfer. The labeler Preferred Pharmaceuticals, Inc. is displayed with a barcode and bilingual dosing directions in English and Spanish.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing a naphthalene group connected to a thiophene ring with an amine group attached to a side chain as represented by the molecular diagram.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine delayed-release capsules treatments. The graph plots relapse proportion on the vertical axis against days on the horizontal axis, illustrating lower relapse rates for duloxetine delayed-release capsules compared to placebo over approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time (days) after randomization between placebo and duloxetine delayed-release capsules. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. The graph shows two lines: a dashed line for placebo and a solid line for duloxetine delayed-release capsules.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Four lines compare different groups: DUL 60mg BD, DUL 60mg OD, DUL 20mg OD, and placebo, illustrating their pain improvement outcomes over a range of percentages.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Three treatment groups are compared: DULOXETINE DELAYED-RELEASE 60 mg twice daily, DULOXETINE DELAYED-RELEASE 60 mg once daily, and placebo. The graph illustrates trends in pain improvement across these groups over a range of improvement percentages.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The graph indicates higher percentages of improvement in pain with Duloxetine doses compared to placebo across the range of pain improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline, comparing DULOXETINE DELAYED-RELEASE dosages of 120 mg, 60 mg, and 20 mg once daily versus placebo. The y-axis represents the percentage of patients improved, and the x-axis represents the percent improvement in pain from baseline.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily versus placebo. The graph shows two curves representing these treatments with improvement percentages plotted along the vertical axis and pain improvement percentages along the horizontal axis.*

FDA Label Image

Duloxetine 09

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two lines compare placebo and Duloxetine (DUL) 60 mg once daily, illustrating higher patient improvement percentages for Duloxetine across pain improvement levels.*

FDA Label Image

Duloxetine Delayed-release Capsules, Usp 30mg (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and DULOXETINE DELAYED-RELEASE 60/120 mg once daily. The graph shows two trend lines indicating patient response rates across varying levels of pain improvement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.